Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cidara Therapeutics (CDTX) Current Deferred Revenue: 2019-2024

Historic Current Deferred Revenue for Cidara Therapeutics (CDTX) over the last 4 years, with Mar 2024 value amounting to $26.2 million.

  • Cidara Therapeutics' Current Deferred Revenue rose 66.00% to $26.2 million in Q1 2024 from the same period last year, while for Mar 2024 it was $26.2 million, marking a year-over-year increase of 66.00%. This contributed to the annual value of $430,000 for FY2023, which is 97.06% down from last year.
  • Cidara Therapeutics' Current Deferred Revenue amounted to $26.2 million in Q1 2024, which was up 5,995.81% from $430,000 recorded in Q4 2023.
  • Cidara Therapeutics' Current Deferred Revenue's 5-year high stood at $30.3 million during Q3 2021, with a 5-year trough of $430,000 in Q4 2023.
  • Its 3-year average for Current Deferred Revenue is $14.5 million, with a median of $14.7 million in 2022.
  • As far as peak fluctuations go, Cidara Therapeutics' Current Deferred Revenue soared by 170.09% in 2021, and later plummeted by 97.06% in 2023.
  • Quarterly analysis of 5 years shows Cidara Therapeutics' Current Deferred Revenue stood at $13.9 million in 2020, then grew by 0.40% to $13.9 million in 2021, then increased by 4.99% to $14.6 million in 2022, then tumbled by 97.06% to $430,000 in 2023, then spiked by 66.00% to $26.2 million in 2024.
  • Its Current Deferred Revenue was $26.2 million in Q1 2024, compared to $430,000 in Q4 2023 and $14.7 million in Q3 2023.